Patents Assigned to Hansa Medical AB
-
Patent number: 10973889Abstract: The invention relates to a method for improving the benefit of a therapy or a therapeutic agent to a subject. The method comprises administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject; and subsequently administering said therapy or said therapeutic agent to the subject. The invention also relates to a method for reducing the effect of pathogenic autoantibodies in a subject, the method comprising (a) administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject and optionally (b) subsequently subjecting the subject to a treatment which removes endogenous autoantibodies. The invention also relates to a kit for carrying out a method of the invention.Type: GrantFiled: July 10, 2015Date of Patent: April 13, 2021Assignee: Hansa Medical ABInventors: Christian Kjellman, Sofia Jarnum, Lena Winstedt
-
Patent number: 10126312Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.Type: GrantFiled: May 12, 2016Date of Patent: November 13, 2018Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 9784741Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: GrantFiled: December 2, 2013Date of Patent: October 10, 2017Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 9759720Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.Type: GrantFiled: September 23, 2011Date of Patent: September 12, 2017Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Patent number: 9707279Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.Type: GrantFiled: March 5, 2012Date of Patent: July 18, 2017Assignee: Hansa Medical ABInventors: Mattias Collin, Rolf Lood, Karl Carlstrom, Maria Allhorn, Jonathan Sjogren, Falk Nimmerjahn
-
Patent number: 8889128Abstract: The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: GrantFiled: December 12, 2007Date of Patent: November 18, 2014Assignee: Hansa Medical ABInventors: Lars Björck, Mattias Collin, Arne Olsén, Rikard Holmdahl, Kutty Selva Nandakumar, Oonagh Shannon
-
Publication number: 20140187503Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: ApplicationFiled: December 2, 2013Publication date: July 3, 2014Applicant: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Publication number: 20140080754Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.Type: ApplicationFiled: September 23, 2011Publication date: March 20, 2014Applicant: HANSA MEDICAL ABInventors: Lars Björck, Bertil Christensson, Adam Linder, Heiko Herwald, Per Åkesson
-
Publication number: 20140080925Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.Type: ApplicationFiled: February 7, 2012Publication date: March 20, 2014Applicant: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Publication number: 20140065128Abstract: The invention provides an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, for use in a method for treating or preventing a disease or condition mediated by IgE antibodies.Type: ApplicationFiled: March 5, 2012Publication date: March 6, 2014Applicant: HANSA MEDICAL ABInventors: Mattias Collin, Rolf Lood, Karl Carlstrom, Maria Allhorn, Jonathan Sjogren, Falk Nimmerjahn
-
Publication number: 20130252347Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: ApplicationFiled: March 12, 2013Publication date: September 26, 2013Applicant: Hansa Medical ABInventors: Lars Bjorck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Akesson
-
Patent number: 8518648Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.Type: GrantFiled: June 12, 2008Date of Patent: August 27, 2013Assignee: Hansa Medical ABInventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
-
Publication number: 20130177547Abstract: The present invention relates to blood coagulation factor XIII (FXIII) for treatment and/or prevention of an infection by a microorganism and/or the symptoms associated with said infection, a pharmaceutical composition comprising a pharmaceutically effective amount of said FXIII, a method for the manufacture of a medicament comprising a pharmaceutically effective amount of said FXIII, and a method of treatment comprising administering to a patient in need a pharmaceutically effective amount of said FXIII.Type: ApplicationFiled: July 20, 2011Publication date: July 11, 2013Applicants: HANSA MEDICAL AB, CSL BEHRING GMBHInventors: Heiko Herwald, Ulrich Theopold, Torsten Loof, Matthias Mörgelin, Gerhard Dickneite
-
Patent number: 8133483Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: GrantFiled: June 8, 2006Date of Patent: March 13, 2012Assignee: Hansa Medical ABInventors: Lars Björck, Rikard Holmdahl, Kutty Selva Nandakumar
-
Publication number: 20110318340Abstract: The present invention provides an antibody, or antibody fragment, with modified glycosylation for use in treating or preventing a disease or condition, where the antibody or fragment: (a) suppresses an inflammatory condition forming part of the disease or condition to be treated or prevented; and/or (b) displays increased efficacy and/or decreased side effects in comparision to treatment or prevention with the corresponding antibody with unmodified glycosylation.Type: ApplicationFiled: November 18, 2009Publication date: December 29, 2011Applicant: Hansa Medical ABInventors: Mattias Collin, Maria Allhorn, Rikard Holmdahl, Kutty Selva Nandakumar
-
Publication number: 20100135981Abstract: The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.Type: ApplicationFiled: December 12, 2007Publication date: June 3, 2010Applicant: Hansa Medical ABInventors: Lars Bjorck, Mattias Collin, Arne Olsen, Rikard Holmdahl, Kutty Selva Nandakumar, Oonagh Shannon
-
Publication number: 20080085853Abstract: A nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; and associated therewith (ii) one or more other components whose targeting to the nucleus of the eukaryotic cell is desired.Type: ApplicationFiled: February 12, 2007Publication date: April 10, 2008Applicant: HANSA MEDICAL ABInventors: Eugen Axcrona, Lars Bjorck, Inga-Maria Frick, Tomas Leandersson
-
Patent number: 7335355Abstract: A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the testType: GrantFiled: July 17, 2001Date of Patent: February 26, 2008Assignee: Hansa Medical ABInventors: Lars Bjorck, Inga-Maria Frick, Artur Schmidtchen
-
Patent number: 7176178Abstract: A nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; and associated therewith (ii) one or more other components whose targeting to the nucleus of the eukaryotic cell is desired.Type: GrantFiled: May 11, 2000Date of Patent: February 13, 2007Assignee: Hansa Medical ABInventors: Lars Henrik Bjorck, Inga-Maria Frick, Tomas Borje Leandersson, Eugen J. K. Axcrona
-
Publication number: 20060205925Abstract: A protein from Streptococcus pyogenes, serotype M1 has been characterized. This protein, called protein SIC, plays a role in S. pyogenes pathogenicity and virulence. It inhibits hemolysis by interacting with the plasma proteins clusterin, and members of the cystatin protein super family such as histidine rich glycoprotein (HRG). The protein, comprises at least one of the following partial amino acid sequences: (a) glu thr tyr thr ser arg asn phe; (b) asp trp ser gly asp asp trp pro glu asp asp trp; (c) arg ser gly val gly leu ser gln tyr gly trp ser; (d) trp ser ser asp lys lys asp glu thr glu asp lys thr; (e) gly thr gly tyr glu lys arg asp asp trp gly gly pro gly; (f) lys arg asp asp trp arg gly pro gly his ile pro lys pro. The protein and antibodies specific for the protein can be used in analytical procedures for determining the presence of virulent Streptococcus pyogenes in a sample. The protein can also be used in vaccine compositions.Type: ApplicationFiled: May 5, 2006Publication date: September 14, 2006Applicant: Hansa Medical ABInventors: Per Akesson, Lars Bjorck, Anders Sjoholm